Arbutus Biopharma
ABUS
ABUS
48 hedge funds and large institutions have $115M invested in Arbutus Biopharma in 2016 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 17 increasing their positions, 14 reducing their positions, and 8 closing their positions.
New
Increased
Maintained
Reduced
Closed
more capital invested
Capital invested by funds: $ → $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more call options, than puts
Call options by funds: $ | Put options by funds: $
less funds holding
Funds holding: →
38% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 8
Holders
48
Holding in Top 10
1
Calls
$880K
Puts
$819K
Top Buyers
| 1 | +$55.1M | |
| 2 | +$3.41M | |
| 3 | +$175K | |
| 4 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
+$152K |
| 5 |
Renaissance Technologies
New York
|
+$130K |
Top Sellers
| 1 | -$1.02M | |
| 2 | -$889K | |
| 3 | -$870K | |
| 4 |
SCM
Suffolk Capital Management
New York
|
-$437K |
| 5 |
Millennium Management
New York
|
-$378K |